# Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct01336023` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01336023](<https://clinicaltrials.gov/study/NCT01336023>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01336023

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1663 participants.

## Technical summary

Registry record NCT01336023. Randomized; no masking; primary purpose treatment. Start 2011-05-23 (actual); primary completion 2012-05-24 (actual). Results posted on 2017-06-02.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1663 participants (enrolled count; ClinicalTrials.gov record NCT01336023, source copy `cardio:ctgov-nct01336023-2018-02-19`, retrieved 2026-10-26)
- Started: 2011-05-23 (actual) (ClinicalTrials.gov record NCT01336023, source copy `cardio:ctgov-nct01336023-2018-02-19`, retrieved 2026-10-26)
- Primary completion: 2012-05-24 (actual) (ClinicalTrials.gov record NCT01336023, source copy `cardio:ctgov-nct01336023-2018-02-19`, retrieved 2026-10-26)
- Completion: 2012-11-22 (actual) (ClinicalTrials.gov record NCT01336023, source copy `cardio:ctgov-nct01336023-2018-02-19`, retrieved 2026-10-26)
- Results first posted: 2017-06-02 (ClinicalTrials.gov record NCT01336023, source copy `cardio:ctgov-nct01336023-2018-02-19`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Finland; Germany; Hungary; India; Ireland; Italy; Malaysia; Mexico; Puerto Rico; Russia; Singapore; Slovakia; South Africa; Spain; Taiwan; Thailand; United Kingdom (ClinicalTrials.gov record NCT01336023, source copy `cardio:ctgov-nct01336023-2018-02-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01336023-2018-02-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
- Acronym: DUAL™ I
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec/liraglutide
- Intervention (Drug): insulin degludec
- Intervention (Drug): liraglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test (`cardio:pubmed-26443290`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes (`cardio:pubmed-25190523`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial (`cardio:pubmed-25980900`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy (`cardio:pubmed-25998481`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges (`cardio:pubmed-28282219`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: dc5177de8c771b369ef6eff51dce3601127ee319ceb0cb5dfa5e0ce9affe6f3e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
